EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment‐Free Remissions in Children With Chronic Myeloid Leukemia ( CML ): A Prospective Study From the Tata Memorial Hospital ( TMH ) Pediatric CML ( pCML ) Cohort

Nirmalya Roy Moulik iD, Swaminathan Keerthivasagam iD, Gaurav Chatterjee iD, Jayesh Agiwale, Pallavi Rane, Chetan Dhamne, Akanksha Chichra, Shyam Srinivasan iD, Purvi Mohanty, Hemani Jain, Dhanlaxmi Shetty, Sweta Rajpal und 5 weitere

American Journal of Hematology · 2025-02 · 100 (2) · 210-217

DOI: 10.1002/ajh.27528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 20.11.2024. Verfasst von Nirmalya Roy Moulik und 16 weiteren Autor:innen. Beteiligte Einrichtung: Tata Memorial Hospital, Pediatric Oncology, Mumbai, India. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Remission Induction, Imatinib Mesylate. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Sohn Conference Foundation, The Sohn Conference Foundation. INR 1 672 000 (Equivalent to 20 400 USD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%–3% of all childhood leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their long‐term effects on growth and bone health in children. We prospectively studied treatment‐free remission (TFR) in 45 children with pCML in chronic phase on imatinib. Eligibility criteria were as per current NCCN guidelines, with a less stringent qPCR monitoring scheduled every 3 months. TFR was successful in 71.1% (32 out of 45) of patients after a median follow‐up of 25 (range: 6–42) months. The TFR rates at 12 and 24 months were 70% and 66%, respectively. Children under 5 years had a TFR rate of 88.9%, compared to 61.8% in those over 5 years ( p = 0.18). Eleven of the 13 patients who lost MMR did so within 6 months of discontinuation. The cumulative incidence of loss in MMR at 6, 12, and 24 months was 26.4%, 27%, and 33%, respectively. Ten out of 13 (76.9%) patients with discontinuation failure (DF) regained MMR within 3 (2–20) months of restarting imatinib. A significant correlation was found between higher T‐regulatory cell levels at baseline and DF ( p = 0.005). More than half patients showed improved bone mineral density after 2 years of TFR. Our findings suggest that high TFR rates can be attained in pCML, with added benefits for bone health. Less frequent molecular monitoring was not associated with adverse outcomes and there seems to be a role of the immune system in sustaining TFR. The study is registered in the Clinical Trials Registry‐India (CTRI/2020/11/029199).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveRemission InductionImatinib MesylateHumansChildProspective StudiesFemaleMaleChild, PreschoolAdolescentInfantProtein Kinase InhibitorsAntineoplastic AgentsFollow-Up Studies

Stichwörter der Autor:innen

TFR in pediatric CMLTKI discontinuationimatinib discontinuationpediatric CML

Substanzen

Imatinib MesylateProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Tata Memorial Hospital, Pediatric Oncology, Mumbai, India.
  • Homi Bhabha National Institute, Mumbai, India.
  • Jawaharlal Institute of Postgraduate Medical Education and Research, Medical Oncology, Puducherry, India.
  • Tata Memorial Hospital, Hematopathology, Mumbai, India.
  • Tata Memorial Hospital, Biostatistics, Mumbai, India.
  • Tata Memorial Hospital, Cancer Cytogenetics, Mumbai, India.

ORCID-Profile: Nirmalya Roy Moulik, Swaminathan Keerthivasagam, Gaurav Chatterjee, Shyam Srinivasan, Prashant Tembhare, Nikhil Patkar

Förderung

  • The Sohn Conference Foundation
  • The Sohn Conference Foundation. INR 1 672 000 (Equivalent to 20 400 USD)

Zitieren

APA

Roy Moulik, N., Keerthivasagam, S., Chatterjee, G., Agiwale, J., Rane, P., Dhamne, C., Chichra, A., Srinivasan, S., Mohanty, P., Jain, H., Shetty, D., Rajpal, S., Tembhare, P., Patkar, N., Narula, G., Subramanian, P. G., & Banavali, S. (2025). Treatment‐Free Remissions in Children With Chronic Myeloid Leukemia ( CML ): A Prospective Study From the Tata Memorial Hospital ( TMH ) Pediatric CML ( pCML ) Cohort. American Journal of Hematology, 100(2), 210-217. https://doi.org/10.1002/ajh.27528

Vancouver

Roy Moulik N, Keerthivasagam S, Chatterjee G, Agiwale J, Rane P, Dhamne C, et al. Treatment‐Free Remissions in Children With Chronic Myeloid Leukemia ( CML ): A Prospective Study From the Tata Memorial Hospital ( TMH ) Pediatric CML ( pCML ) Cohort. American Journal of Hematology. 2025;100(2):210-217. doi:10.1002/ajh.27528

BibTeX
@article{RoyMoulik2025,
  author = {Roy Moulik, Nirmalya and Keerthivasagam, Swaminathan and Chatterjee, Gaurav and Agiwale, Jayesh and Rane, Pallavi and Dhamne, Chetan and Chichra, Akanksha and Srinivasan, Shyam and Mohanty, Purvi and Jain, Hemani and Shetty, Dhanlaxmi and Rajpal, Sweta and Tembhare, Prashant and Patkar, Nikhil and Narula, Gaurav and Subramanian, Papagudi G and Banavali, Shripad},
  title = {Treatment‐Free Remissions in Children With Chronic Myeloid Leukemia ( CML ): A Prospective Study From the Tata Memorial Hospital ( TMH ) Pediatric CML ( pCML ) Cohort},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {2},
  pages = {210--217},
  doi = {10.1002/ajh.27528}
}
Kostenlos starten →